| 4:40 PM | Standardizing the Language on Bleeding and Ischemic Risks: Insights on ARC, BARC, VARC, and Others Lecturer: Pieter Smits |
| 4:48 PM | Escalation Strategy of Antithrombotic Therapy: Why, in Whom, and How? Lecturer: Tullio Palmerini |
| 4:56 PM | De-Escalation Strategy of Antithrombotic Therapy: Why, in Whom, and How? Lecturer: Sripal Bangalore |
| 5:04 PM | Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial Lecturer: Duk-Woo Park |
| 5:12 PM | Panel Discussion l |
| 5:27 PM | Don't Forget About Dual Pathway Inhibition: When DOAC Should Not Be Standard Treatment Lecturer: Dominick J. Angiolillo |
| 5:35 PM | Factor XI Inhibitors in Availalbe RCTs: A Meta-analysis and Future Perspectives Lecturer: Roxana Mehran |
| 5:43 PM | Long-term DOAC Management of AF and Stable CAD: Expectation on the EPIC-CAD Trial After the AFIRE Trial Lecturer: Gi-Byoung Nam |
| 5:51 PM | Panel Discussion ll |